Publications by authors named "Paul A Reilly"

Claim this Profile
D
Dabigatran Reversal With Idarucizumab in Patients Requiring Urgent Surgery: A Subanalysis of the RE-VERSE AD Study.
Jerrold H Levy, Joanne van Ryn, Frank W Sellke, Paul A Reilly, Amelie Elsaesser

Ann Surg· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study.
Samuel Z Goldhaber, Walter Ageno, Ivan B Casella, Kok Han Chee, Sebastian Schellong, Paul A Reilly

Am J Med· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program.
John Fanikos, Debra Murwin, Fredrik Gruenenfelder, Igor Tartakovsky, Lionel Riou França, Paul A Reilly

Thromb Haemost· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation.
Anthony P Kent, Martina Brueckmann, Mandy Fraessdorf, Stuart J Connolly, Salim Yusuf, Paul A Reilly

J Am Coll Cardiol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis.
Ziad Hijazi, Stefan H Hohnloser, Jonas Oldgren, Ulrika Andersson, Stuart J Connolly, Paul A Reilly

Am Heart J· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism.
Manuela Albisetti, Arno Schlosser, Martina Brueckmann, Savion Gropper, Stephan Glund, Paul A Reilly

Res Pract Thromb Haemost· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dabigatran Reversal with Idarucizumab.
Charles V Pollack, Paul A Reilly, Jeffrey I Weitz

N Engl J Med· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study.
Masahiro Yasaka, Ippei Ikushima, Akiko Harada, Susumu Imazu, Atsushi Taniguchi, Paul A Reilly

Res Pract Thromb Haemost· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the immunogenicity of the dabigatran reversal agent idarucizumab during Phase I studies.
Stephen Norris, Steven Ramael, Ippei Ikushima, Wouter Haazen, Akiko Harada, Paul A Reilly

Br J Clin Pharmacol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Idarucizumab for Dabigatran Reversal - Full Cohort Analysis.
Charles V Pollack, Paul A Reilly, Joanne van Ryn, John W Eikelboom, Stephan Glund

N Engl J Med· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
Ziad Hijazi, Jonas Oldgren, Ulrika Andersson, Stuart J Connolly, John W Eikelboom, Paul A Reilly

Am Heart J· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Successful use of idarucizumab as a reversal agent for dabigatran in a patient with acute dissected aortic aneurysm.
Anna Tomaszuk-Kazberuk, Paulina Łopatowska, Elżbieta Młodawska, Joanne van Ryn, Paul A Reilly

Pol Arch Intern Med· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects.
Paul A Reilly, Joanne van Ryn, Oliver Grottke, Stephan Glund, Joachim Stangier

Am J Med· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Idarucizumab, a specific reversal agent for dabigatran: mode of action, pharmacokinetics and pharmacodynamics, and safety and efficacy in phase 1 subjects.
Paul A Reilly, Joanne van Ryn, Oliver Grottke, Stephan Glund, Joachim Stangier

Am J Emerg Med· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy).
Michael D Ezekowitz, Rangadham Nagarakanti, Herbert Noack, Martina Brueckmann, Claire Litherland, Paul A Reilly

Circulation· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Dabigatran Etexilate vs. Warfarin in Asian RE-LY Patients According to Baseline Renal Function or CHADS2 Score.
Masatsugu Hori, Taku Fukaya, Eva Kleine, Paul A Reilly, Michael D Ezekowitz

Circ J· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation.
Michael D Ezekowitz, John Eikelboom, Jonas Oldgren, Paul A Reilly, Martina Brueckmann

Europace· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
D-dimer and factor VIIa in atrial fibrillation - prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy.
Agneta Siegbahn, Jonas Oldgren, Ulrika Andersson, Michael D Ezekowitz, Paul A Reilly

Thromb Haemost· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Letter to the Editor: Managing Dabigatran-Related Bleeding.
Jerrold H Levy, Jeffrey I Weitz, Richard A Bernstein, John Eikelboom, Elaine Hylek, Paul A Reilly

J Intensive Care Med· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply: Anticoagulant-Related Nephropathy.
Michael Böhm, Michael D Ezekowitz, Stuart J Connolly, John W Eikelboom, Stefan H Hohnloser, Paul A Reilly

J Am Coll Cardiol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation.
Julia Aulin, Agneta Siegbahn, Ziad Hijazi, Michael D Ezekowitz, Ulrika Andersson, Paul A Reilly

Am Heart J· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Idarucizumab for Dabigatran Reversal.
Charles V Pollack, Paul A Reilly, John Eikelboom, Stephan Glund, Peter Verhamme

N Engl J Med· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran.
Charles V Pollack, Paul A Reilly, Richard Bernstein, Robert Dubiel, John Eikelboom

Thromb Haemost· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel oral anticoagulants and reversal agents: Considerations for clinical development.
Troy C Sarich, Jonathan H Seltzer, Scott D Berkowitz, James Costin', John T Curnutte, Paul A Reilly

Am Heart J· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial.
Michael Böhm, Michael D Ezekowitz, Stuart J Connolly, John W Eikelboom, Stefan H Hohnloser, Paul A Reilly

J Am Coll Cardiol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis